Pfizer’s COVID-19 product sales plummet, but new blockbuster drugs in the pipeline show promise. Cancer treatments acquired from Seagen drive growth, with Padcev sales up 38% to $2.2 billion annually. Elrexfio, another cancer therapy, could generate over $5 billion in peak sales. Pfizer’s post-COVID future looks bright.

Despite a sharp decline in sales of Comirnaty and Paxlovid, Pfizer’s post-COVID prospects are looking up. The company invested heavily in Seagen’s cancer treatments, with Padcev sales rising by 38% to $2.2 billion annually. Elrexfio, approved to treat multiple myeloma patients, also shows promising results. Pfizer’s future looks promising with these new therapies.

Investing in Pfizer? Consider this: Motley Fool’s Stock Advisor team picked the 10 best stocks to buy now, and Pfizer didn’t make the cut. The selected stocks could yield significant returns in the future, similar to Netflix and Nvidia, which saw massive growth after being recommended by the team. Make an informed decision before investing in Pfizer.

Read more at Yahoo Finance: Why Pfizer’s Post-COVID Future Looks Brighter Than Ever